Qualcomm (QCOM) Shareholder Convergence Investment Partners Upped Its Stake by $2.39 Million; Atara Biotherapeutics (ATRA) Holding Maintained by Tiverton Asset Management Llc

QUALCOMM Incorporated (NASDAQ:QCOM) Logo

Convergence Investment Partners Llc increased its stake in Qualcomm Inc (QCOM) by 118.7% based on its latest 2018Q3 regulatory filing with the SEC. Convergence Investment Partners Llc bought 33,227 shares as the company’s stock declined 20.85% with the market. The institutional investor held 61,220 shares of the radio and television broadcasting and communications equipment company at the end of 2018Q3, valued at $4.41M, up from 27,993 at the end of the previous reported quarter. Convergence Investment Partners Llc who had been investing in Qualcomm Inc for a number of months, seems to be bullish on the $62.44B market cap company. The stock decreased 0.14% or $0.07 during the last trading session, reaching $51.59. About 1,970 shares traded. QUALCOMM Incorporated (NASDAQ:QCOM) has declined 12.25% since February 14, 2018 and is downtrending. It has underperformed by 12.25% the S&P500. Some Historical QCOM News: 13/04/2018 – China Stalls Review of Qualcomm, Toshiba Deals; 20/03/2018 – lnnovium Announces Sampling of TERALYNX™ 12.8 Tbps Data-Center Optimized Switch; 28/03/2018 – NXP/Qualcomm face MOFCOM meeting delay, sources say [16:09 BST28 Mar 2018] [Proprietary] []; 06/03/2018 – Treasury Voices Worries Over Qualcomm Takeover (Audio); 23/03/2018 – Qualcomm Extends NXP Tender Offer to April 2; 06/03/2018 – Qualcomm: Treasury Letter Slams Broadcom for Cost-Cutting Approach — Barron’s Blog; 07/03/2018 – HAYMAN’S BASS SAID U.S. CAN’T LET QUALCOMM/AVGO DEAL GO THROUGH; 23/05/2018 – Qualcomm Snapdragon 710 Mobile Platform Brings In-Demand Premium Features to a New Tier of Smartphones; 15/03/2018 – BROADCOM LTD-QUALCOMM WAS CLEARLY A UNIQUE AND VERY LARGE ACQUISITION OPPORTUNITY- CFO, CONF CALL; 13/03/2018 – WASHINGTON/PALO ALTO, U.S. — U.S. President Donald Trump’s decision Monday to block Singaporean chipmaker Broadcom’s bid for American peer Qualcomm on national security grounds is not the first time his administration has used such reasoning to shield U.S. businesses from Chinese competition

Tiverton Asset Management Llc increased its stake in Atara Biotherapeutics Inc (ATRA) by 18.12% based on its latest 2018Q3 regulatory filing with the SEC. Tiverton Asset Management Llc bought 15,825 shares as the company’s stock rose 8.10% while stock markets declined. The institutional investor held 103,158 shares of the health care company at the end of 2018Q3, valued at $4.27M, up from 87,333 at the end of the previous reported quarter. Tiverton Asset Management Llc who had been investing in Atara Biotherapeutics Inc for a number of months, seems to be bullish on the $1.79 billion market cap company. The stock decreased 0.10% or $0.04 during the last trading session, reaching $39.23. About 255,041 shares traded. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has risen 213.65% since February 14, 2018 and is uptrending. It has outperformed by 213.65% the S&P500. Some Historical ATRA News: 08/05/2018 – Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies in Oncology, Aut; 21/04/2018 – DJ Atara Biotherapeutics Inc, Inst Holders, 1Q 2018 (ATRA); 01/05/2018 – Atara Biotherapeutics Expands Comml Leadership Team With the Appointment of Manuela Maronati as General Manager, Europe; 08/05/2018 – Atara Biotherapeutics 1Q Loss/Shr $1.05; 14/05/2018 – T Rowe Price Associates Buys New 3.9% Position in Atara Bio; 29/05/2018 – Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences; 17/05/2018 – Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association; 14/05/2018 – Rounds Report: Omeros Rallied While The Stellar FDA Due Diligence To Help Atara; 26/03/2018 – Atara Bio Presenting at Conference Tomorrow; 07/05/2018 – Biotech Industry Veteran Dietmar Berger, M.D., Ph.D., Joins Atara Biotherapeutics as Global Head of Research and Development

Investors sentiment decreased to 1.07 in Q3 2018. Its down 0.82, from 1.89 in 2018Q2. It is negative, as 15 investors sold ATRA shares while 27 reduced holdings. 14 funds opened positions while 31 raised stakes. 43.89 million shares or 1.39% less from 44.51 million shares in 2018Q2 were reported. National Bank & Trust Of America Corporation De holds 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 141,615 shares. Neuberger Berman Grp Ltd holds 0.06% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) or 1.22M shares. Tocqueville Asset Mngmt Lp reported 0.01% stake. Tiaa Cref Investment Mgmt Limited reported 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Eagle Asset Incorporated holds 0.32% or 1.62 million shares. Ny State Common Retirement Fund reported 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Moreover, Northern Trust Corp has 0.01% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 524,072 shares. National Bank Of New York Mellon Corp holds 179,505 shares or 0% of its portfolio. Eaton Vance Management holds 0% or 48,806 shares in its portfolio. Swiss National Bank & Trust has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 52,600 shares. Old West Investment Mgmt Ltd Liability Company reported 9,984 shares stake. Moreover, Redmile Grp Inc has 5.36% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 4.22M shares. Switzerland-based Credit Suisse Ag has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Prelude Cap Management stated it has 0.01% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Great West Life Assurance Can stated it has 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA).

Among 11 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 7 have Buy rating, 1 Sell and 3 Hold. Therefore 64% are positive. Atara Biotherapeutics had 29 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, January 30. The rating was reinitiated by Jefferies with “Buy” on Monday, October 24. The firm earned “Buy” rating on Tuesday, April 10 by J.P. Morgan. The company was maintained on Monday, March 5 by Jefferies. Jefferies maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rating on Thursday, August 31. Jefferies has “Buy” rating and $30.0 target. On Thursday, June 22 the stock rating was reinitiated by Jefferies with “Buy”. JMP Securities maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rating on Tuesday, December 15. JMP Securities has “Market Outperform” rating and $40 target. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. William Blair maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Friday, April 6 with “Buy” rating. Citigroup downgraded the stock to “Sell” rating in Thursday, February 15 report.

Tiverton Asset Management Llc, which manages about $2.04B US Long portfolio, decreased its stake in Lowe’s Cos Inc (NYSE:LOW) by 3,986 shares to 5,914 shares, valued at $679,000 in 2018Q3, according to the filing. It also reduced its holding in Costco Wholesale Corp (NASDAQ:COST) by 1,455 shares in the quarter, leaving it with 64,268 shares, and cut its stake in Kinder Morgan Inc/De (NYSE:KMI).

Since August 15, 2018, it had 0 insider purchases, and 25 sales for $7.88 million activity. The insider Newell Joe sold 1,500 shares worth $59,178. $283,647 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares were sold by Ciechanover Isaac E.. Shares for $363,500 were sold by MARCUS JOEL S on Wednesday, November 7. $777,586 worth of stock was sold by Gallagher Carol Giltner on Wednesday, November 7.

More notable recent Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news were published by: Seekingalpha.com which released: “Key events next week – healthcare – Seeking Alpha” on November 23, 2018, also Globenewswire.com with their article: “Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS) – GlobeNewswire” published on December 15, 2018, Seekingalpha.com published: “Atara: Forecasting The Upcoming Clinical Binary Of Tab-Cel – Seeking Alpha” on October 08, 2018. More interesting news about Atara Biotherapeutics, Inc. (NASDAQ:ATRA) were released by: Globenewswire.com and their article: “Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock – GlobeNewswire” published on January 03, 2018 as well as Globenewswire.com‘s news article titled: “Atara Biotherapeutics Announces Planned Chief Executive Officer Transition – GlobeNewswire” with publication date: January 03, 2019.

Convergence Investment Partners Llc, which manages about $492.68M and $490.50 million US Long portfolio, decreased its stake in Manhattan Assocs Inc (NASDAQ:MANH) by 17,984 shares to 11,578 shares, valued at $632,000 in 2018Q3, according to the filing. It also reduced its holding in Phillips 66 (NYSE:PSX) by 14,720 shares in the quarter, leaving it with 19,269 shares, and cut its stake in Citizens Finl Group Inc (NYSE:CFG).

Among 37 analysts covering Qualcomm Inc. (NASDAQ:QCOM), 16 have Buy rating, 1 Sell and 20 Hold. Therefore 43% are positive. Qualcomm Inc. had 171 analyst reports since July 23, 2015 according to SRatingsIntel. On Thursday, June 15 the stock rating was maintained by Susquehanna with “Buy”. Morgan Stanley upgraded the stock to “Equal-Weight” rating in Friday, November 16 report. The stock has “Buy” rating by Canaccord Genuity on Tuesday, January 16. Bernstein maintained the shares of QCOM in report on Wednesday, July 19 with “Hold” rating. The firm has “Outperform” rating by Cowen & Co given on Thursday, November 5. The firm has “Hold” rating by RBC Capital Markets given on Monday, October 30. Mizuho maintained QUALCOMM Incorporated (NASDAQ:QCOM) on Thursday, January 14 with “Neutral” rating. The company was downgraded on Monday, January 23 by CLSA. The stock of QUALCOMM Incorporated (NASDAQ:QCOM) has “Overweight” rating given on Thursday, February 1 by KeyBanc Capital Markets. Canaccord Genuity maintained QUALCOMM Incorporated (NASDAQ:QCOM) rating on Wednesday, November 1. Canaccord Genuity has “Buy” rating and $70.0 target.

More notable recent QUALCOMM Incorporated (NASDAQ:QCOM) news were published by: Nasdaq.com which released: “Will Lower Revenues Hurt QUALCOMM’s (QCOM) Q1 Earnings? – Nasdaq” on January 28, 2019, also Nasdaq.com with their article: “Qualcomm (QCOM) Reports Next Week: Wall Street Expects Earnings Growth – Nasdaq” published on January 23, 2019, Nasdaq.com published: “Qualcomm Holds Pattern Favoring Long Trade off Post-Market Earnings Moves – Nasdaq” on January 29, 2019. More interesting news about QUALCOMM Incorporated (NASDAQ:QCOM) were released by: Nasdaq.com and their article: “Wednesday Apple Rumors: Apple May Alter iPhone 7 & 8 For German Sales – Nasdaq” published on February 06, 2019 as well as Investorplace.com‘s news article titled: “Is QCOM Stock Poised for an Epic Implosion? – Investorplace.com” with publication date: January 25, 2019.

Investors sentiment decreased to 0.77 in Q3 2018. Its down 0.17, from 0.94 in 2018Q2. It fall, as 48 investors sold QCOM shares while 521 reduced holdings. 153 funds opened positions while 285 raised stakes. 1.05 billion shares or 4.81% less from 1.10 billion shares in 2018Q2 were reported. Woodstock Corp accumulated 1.11% or 91,304 shares. The New York-based Pinnacle Assocs has invested 0.08% in QUALCOMM Incorporated (NASDAQ:QCOM). Acadian Asset Mngmt reported 0% stake. Natl Insur Tx invested in 0.34% or 94,882 shares. Cleararc Capital accumulated 0.47% or 49,631 shares. Park Circle Com stated it has 900 shares. Abner Herrman Brock Limited Liability Com accumulated 0.21% or 20,400 shares. Guardian Capital Advisors LP reported 1.09% in QUALCOMM Incorporated (NASDAQ:QCOM). Meridian Inv Counsel holds 0.73% or 18,651 shares in its portfolio. 61,989 were reported by Virtu Ltd Com. Caisse De Depot Et Placement Du Quebec invested in 1.7% or 10.19 million shares. Utah Retirement Systems holds 275,858 shares or 0.38% of its portfolio. Ironsides Asset Advisors Limited Liability Corporation owns 21,121 shares or 0.46% of their US portfolio. Rhumbline Advisers stated it has 0.35% in QUALCOMM Incorporated (NASDAQ:QCOM). Quantum Management has invested 0.45% in QUALCOMM Incorporated (NASDAQ:QCOM).

QUALCOMM Incorporated (NASDAQ:QCOM) Institutional Positions Chart